New York's biotechnology sector thrives at the intersection of science and commercialization, with companies focusing on drug development, diagnostics, and therapeutic innovations. These biotechs leverage groundbreaking research to address critical health issues such as cancer, neurodegenerative disorders, and infectious diseases. As healthcare demands evolve, the industry is shifting towards precision medicine and sustainable health solutions, driving the need for innovative therapies and advanced technologies. Collaborations with academic institutions and investments in research are pivotal in shaping the future of biotechnology, making New York a pivotal player in medical advancements.

The biotechnology companies in this list are primarily startups and growth-stage firms, mostly founded after 2000. Operating in various capacities, these companies range from small teams to mid-sized organizations, with staff numbers between 1 and 200. The firms are headquartered predominantly in New York City and its suburbs, specializing in areas like immunotherapy, gene therapy, and targeted drug development. Noteworthy organizations like Stablix, Inc. and Seed Therapeutics lead the charge in pioneering new treatments, showcasing a strong focus on collaborative innovation to enhance human health.

Read on to discover the top biotechnology companies in New York.

Top 20 Biotechnology Companies Companies in New York

1. Stablix, Inc.

• Website: stablix.com
• Ownership type: Venture Capital
• Headquarters: New York, New York, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Series A, $63.0M, June 2021
• Founded year: 2021
• Headcount: 11-50
• LinkedIn: stablix

Stablix, Inc. is a biotechnology firm based in New York City and Boston, established in 2021. The company specializes in targeted protein stabilization and deubiquitination therapeutics, focusing on developing small-molecule medicines that aim to restore protein function in patients suffering from various diseases, including cancer and rare disorders. Their innovative RESTORED™ platform employs advanced scientific methods to create therapeutic solutions tailored for pharmaceutical companies and research institutions. Stablix has attracted significant investment, raising $63 million in a Series A funding round led by prominent venture capital firms. The company is actively advancing its lead programs towards clinical studies and has formed strategic collaborations, such as with Vertex Pharmaceuticals, to further enhance its research and development capabilities. Stablix's commitment to addressing unmet medical needs positions it as a noteworthy player in the biotechnology industry.

2. Seed Therapeutics

• Website: seedtherapeutics.com
• Ownership type: Venture Capital
• Headquarters: New York, New York, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Series A, $24.0M, August 2024
• Founded year: 2019
• Headcount: 11-50
• LinkedIn: seed-therapeutics

Seed Therapeutics is a biotechnology firm based in New York, specializing in drug discovery and development. Established in 2019, the company is dedicated to creating innovative therapies using molecular glues and targeted protein degradation techniques. These methods aim to tackle disease-causing proteins that have traditionally been considered undruggable. Seed Therapeutics collaborates with prominent pharmaceutical companies, including Eli Lilly and Eisai, to develop treatments for severe diseases, particularly in oncology and neurodegeneration. The company has recently secured $24 million in Series A funding, which underscores its potential and the interest it has garnered in the biotech sector. With a focused mission to improve human health through novel therapeutic approaches, Seed Therapeutics is actively building a pipeline of drug candidates poised for clinical development.

3. Paratus Sciences

• Website: paratussciences.com
• Ownership type: Venture Capital
• Headquarters: New York, New York, United States (USA)
• Employee distribution: United States (USA) 70%, Singapore 30%
• Latest funding: Series A, $100.0M, February 2023
• Founded year: 2021
• Headcount: 11-50
• LinkedIn: paratus-sciences

Paratus Sciences, founded in 2021 and based in New York, is a biotechnology firm dedicated to harnessing the unique biological traits of bats to develop innovative therapeutics. The company focuses on addressing complex diseases such as inflammation and cardiometabolic disorders by studying the evolutionary adaptations of bats. Their research combines genomics and informatics to identify promising therapeutic targets, which they validate through rigorous scientific processes. Paratus has established partnerships with pharmaceutical companies and research institutions, enhancing their capacity for advanced therapeutic solutions. In February 2023, they secured $100 million in Series A funding, reflecting strong investor interest in their pioneering approach. With a team of experts from prestigious institutions, Paratus is positioned to make significant contributions to human health through their unique insights into bat biology.

4. Codagenix Inc.

• Website: codagenix.com
• Ownership type: Venture Capital
• Headquarters: Farmingdale, New York, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Other (Grant), $5.9M, October 2023
• Founded year: 2011
• Headcount: 11-50
• LinkedIn: codagenix

Codagenix Inc., based in Farmingdale, New York, is a biotechnology firm founded in 2011. The company specializes in the development of vaccines and viral therapeutics aimed at combating infectious diseases and cancer. Codagenix employs a unique synthetic biology-driven platform that allows for the precise engineering of viral genomes, resulting in live-attenuated vaccines that promise enhanced safety and efficacy. Their pipeline includes candidates for various diseases, such as COVID-19, RSV, and influenza, as well as innovative cancer therapies. Recently, Codagenix secured $5.88 million in funding through a grant, reflecting their active engagement in research and development. The company collaborates with global health organizations to ensure their solutions reach those in need, demonstrating a commitment to improving public health on a broader scale.

5. Creative Biolabs

• Website: creative-biolabs.com
• Ownership type: Private
• Headquarters: New York, New York, United States (USA)
• Employee distribution: United States (USA) 100%
• Founded year: 2005
• Headcount: 51-200
• LinkedIn: creative-biolabs

Creative Biolabs, founded in 2005 and based in New York, is a private biotechnology service provider that specializes in custom antibody discovery, engineering, and manufacturing solutions. The company serves a wide range of clients, including researchers and pharmaceutical firms, by offering a comprehensive array of services designed to advance drug development and therapeutic applications. With a strong emphasis on high-quality, tailored solutions, Creative Biolabs has established itself as a significant player in the biotechnology and pharmaceutical sectors. Their expertise spans various technologies, including phage display, yeast display, and hybridoma methods, allowing them to cater to specific client needs. The company operates entirely within the United States and has built a reputation for its commitment to quality and innovation in antibody development.

6. Creative BioMart

• Website: creativebiomart.net
• Ownership type: Private
• Headquarters: Shirley, New York, United States (USA)
• Employee distribution: United States (USA) 100%
• Founded year: 2005
• Headcount: 51-200
• LinkedIn: creative-biomart

Creative BioMart, founded in 2005 and based in Shirley, New York, is a private biotechnology company that specializes in therapeutic proteins and testing services. The company caters to researchers and organizations within the pharmaceutical and healthcare sectors, focusing on drug development and safety testing. Creative BioMart offers a wide array of products, including recombinant proteins, vaccine antigens, and stable cell line construction services. Their commitment to quality is reflected in their provision of over 5,000 proteins in stock, aimed at accelerating scientific research and serving as industrial raw materials. The company also provides custom solutions and analytical services, which are crucial for advancing drug discovery programs. With a dedicated team of scientists, Creative BioMart collaborates with clients to enhance the efficacy and safety of therapeutic products, thereby playing a significant role in the biotechnology field.

7. Remix Therapeutics

• Website: remixtx.com
• Ownership type: Venture Capital
• Headquarters: Watertown, New York, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: $60.0M, January 2024
• Founded year: 2018
• Headcount: 51-200
• LinkedIn: remix-therapeutics

Remix Therapeutics, founded in 2018 and based in Watertown, New York, is a biotechnology company dedicated to developing innovative small molecule therapies that modulate RNA processing. The company aims to address significant medical needs, particularly in the fields of cancer and neurodegenerative disorders. Remix has established a proprietary drug discovery platform known as REMaster™, which is designed to identify and develop small molecules that can effectively control gene and protein expression. This platform has enabled the company to generate multiple drug discovery programs that are advancing toward clinical trials. Currently, Remix is conducting Phase 1 clinical trials for its lead candidate, REM-422, which targets adenoid cystic carcinoma and acute myeloid leukemia. The company has also received substantial funding, including a recent $60 million investment in January 2024, and has formed strategic collaborations with major pharmaceutical companies such as Roche and Johnson & Johnson, enhancing its position in the biotechnology industry.

8. Deerfield Management

• Website: deerfield.com
• Ownership type: Private
• Headquarters: New York, New York, United States (USA)
• Employee distribution: United States (USA) 97%, China 3%
• Latest funding: Other (Grant), $25.0M, March 2023
• Founded year: 1994
• Headcount: 51-200
• LinkedIn: deerfield-management

Deerfield Management Company, founded in 1994 and based in New York City, is an investment firm dedicated to advancing healthcare through a combination of information, investment, and philanthropy. The firm manages over $14.6 billion in assets and maintains a portfolio of more than 200 investments across life sciences, medical devices, diagnostics, digital health, and health services. Deerfield is actively involved in the biotechnology sector, providing flexible funding models and strategic support to companies at various stages of development. The firm collaborates with academic research centers to accelerate the commercialization of discoveries, having created numerous spin-off companies that focus on innovative therapeutic solutions. Additionally, Deerfield's philanthropic arm, the Deerfield Foundation, aims to improve health and promote equity in healthcare initiatives. Recently, the firm has also engaged in significant funding activities, including a $25 million grant in March 2023, further solidifying its commitment to advancing healthcare innovations.

9. Ancilia Biosciences

• Website: anciliabio.com
• Ownership type: Venture Capital
• Headquarters: New York, New York, United States (USA)
• Employee distribution: United States (USA) 87%, United Kingdom (UK) 13%
• Latest funding: $4.2M, July 2024
• Founded year: 2019
• Headcount: 1-10
• LinkedIn: ancilia

Ancilia Biosciences, founded in 2019 and based in New York, specializes in CRISPR-mediated solutions aimed at enhancing viral immunity. The company is dedicated to developing innovative products, including live biotherapeutics that leverage beneficial bacteria. Their research and development efforts are concentrated on the virome, which is the collection of viruses that can impact health and disease. Ancilia's clientele includes businesses in both healthcare and agriculture, seeking advanced therapeutic solutions. Recently, they secured $4.2 million in funding, reflecting their potential for growth and innovation in the biotechnology sector. With a small team of dedicated scientists, Ancilia is positioned to make significant contributions to the understanding and application of microbiome science.

10. OnCusp Therapeutics

• Website: oncusptx.com
• Ownership type: Venture Capital
• Headquarters: New York, New York, United States (USA)
• Employee distribution: United States (USA) 50%, China 50%
• Latest funding: Series A, $100.0M, January 2024
• Founded year: 2021
• Headcount: 11-50
• LinkedIn: oncusp-therapeutics

OnCusp Therapeutics is a biotechnology firm based in New York, established in 2021. The company is dedicated to developing innovative treatments for cancer, leveraging its expertise in clinical development and a robust network within the industry. OnCusp focuses on transforming promising research assets into effective therapies, primarily targeting solid tumors. Their current pipeline includes CUSP06, a CDH6 antibody-drug conjugate, which is in Phase 1 trials for treating platinum-refractory ovarian cancer and other advanced solid tumors. The company has recently raised $100 million in Series A funding, which will support its ongoing research and development initiatives. OnCusp's strategic partnerships with pharmaceutical companies and academic researchers further enhance its position in the oncology field, aiming to accelerate the development of first-in-class therapies.

11. Casdin Capital, LLC

• Website: casdincapital.com
• Ownership type: Private
• Headquarters: New York, New York, United States (USA)
• Employee distribution: United States (USA) 100%
• Founded year: 2012
• Headcount: 11-50
• LinkedIn: casdin-capital-llc

Casdin Capital, LLC is a private investment firm based in New York, founded in 2012. The firm specializes in the life sciences sector, focusing on healthcare, biotechnology, synthetic biology, and technology. With a team of experts, Casdin Capital aims to identify and invest in innovative companies that are at the forefront of scientific advancements. They provide not only capital but also strategic partnerships to help these companies grow and succeed. Their portfolio includes a range of ventures that are transforming the life sciences landscape, showcasing their commitment to fostering innovation in biotechnology and related fields. Casdin Capital's approach is rooted in a deep understanding of the market and a long-term vision for the future of healthcare and biotechnology.

12. Avoro Capital

• Website: avorocapital.com
• Ownership type: Private
• Headquarters: New York, New York, United States (USA)
• Employee distribution: United States (USA) 100%
• Founded year: 2010
• Headcount: 11-50
• LinkedIn: venbio-select-advisor

Avoro Capital Advisors, based in New York, is an investment firm that concentrates on the life sciences sector. Founded in 2010, the firm focuses on providing both financial backing and intellectual resources to emerging biotechnology companies. Their investment strategy spans both public and private markets, targeting opportunities from pre-clinical stages to mature commercial therapies. Avoro Capital has a notable portfolio that includes various biotechnology firms, indicating their active involvement in the industry. They aim to identify unique investment opportunities and support companies throughout the investment lifecycle, which is crucial for fostering innovation in biotechnology.

13. Ichor Biologics

• Website: ichorbiologics.com
• Ownership type: Private
• Headquarters: New York, New York, United States (USA)
• Employee distribution: India 95%, United States (USA) 5%
• Founded year: 2014
• Headcount: 1-10
• LinkedIn: ichor-biologics

Ichor Biologics is a New York City-based biotechnology company founded in 2014, dedicated to developing antibody-based therapeutics aimed at combating infectious diseases. The company has created a novel platform that isolates naturally occurring human monoclonal antibodies, which are crucial for creating effective treatments. Ichor's team consists of skilled scientists with expertise in immunology and infectious diseases, working to accelerate the development of therapeutics that are both safe and clinically effective. Their research has led to significant findings, including the protection of animals against lethal hantavirus infections, showcasing the potential of their antibody-based drugs. Ichor has also received grants from the National Institutes of Health to further its research, indicating recognition and support from established health organizations. This focus on infectious diseases, combined with their innovative technology, positions Ichor Biologics as a relevant player in the biotechnology sector.

14. Sanavia Oncology Inc.

• Website: sanavia.bio
• Ownership type: Private
• Headquarters: New York, New York, United States (USA)
• Employee distribution: United States (USA) 100%
• Founded year: 2020
• Headcount: 11-50
• LinkedIn: sanavia-oncology

Sanavia Oncology Inc. is a New York-based biotechnology company founded in 2020, dedicated to developing innovative immunotherapies to combat drug-resistant cancer. The company aims to enhance patient outcomes through advanced scientific research and technology. Their team comprises drug developers with backgrounds from renowned institutions such as Memorial Sloan-Kettering Cancer Center, Rockefeller University, Weill Cornell Medicine, and Columbia University. Sanavia employs a proprietary discovery platform that utilizes high throughput sequencing, single-molecule super-resolution microscopy, and artificial intelligence to identify cancer-specific epitopes in drug-resistant tumors. This approach allows them to generate antibodies with high specificity, targeting the unique challenges posed by drug resistance in cancer therapy. Sanavia's mission is to improve the lives of cancer patients who currently do not benefit from existing therapies, making them a notable entity in the biotechnology field.

15. Cambrian Bio

• Website: cambrianbio.com
• Ownership type: Venture Capital
• Headquarters: New York, New York, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: July 2023
• Founded year: 2019
• Headcount: 11-50
• LinkedIn: cambrianbio

Cambrian Bio, founded in 2019 and based in New York, is a biotechnology company dedicated to developing innovative therapeutics for chronic diseases and age-related conditions. The company operates with a clear mission: to extend healthspan by creating effective and safe therapies. Cambrian collaborates with scientists to understand the biological mechanisms of aging, aiming to bring new classes of medicines to patients. Their approach involves a distributed model that allows for efficient advancement of multiple scientific breakthroughs simultaneously. Cambrian's pipeline includes various programs targeting the mechanistic drivers of aging, with a focus on transforming treatments from reactive to preventive. The company is committed to making these therapies widely available, reflecting their dedication to improving the quality of life for individuals worldwide.

16. Two River

• Website: tworiver.com
• Ownership type: Private
• Headquarters: New York, New York, United States (USA)
• Employee distribution: United States (USA) 100%
• Founded year: 2004
• Headcount: 1-10
• LinkedIn: two-river

Two River is an investment firm based in New York, established in 2004. The company specializes in the life sciences sector, focusing on biotechnology and pharmaceuticals. They partner with scientific founders to create and support companies that develop innovative therapies aimed at improving patient outcomes. Two River invests its own capital into ventures with strong intellectual property and proven leadership teams. Their approach includes providing operational support, corporate development, and strategic guidance, which are crucial for the success of their portfolio companies. Their investments span various areas, including oncology and immunotherapy, showcasing their commitment to advancing healthcare through innovative science.

17. Medical Excellence Capital, LLC

• Website: medexcelcap.com
• Ownership type: Private
• Headquarters: New York, New York, United States (USA)
• Employee distribution: United States (USA) 100%
• Founded year: 2020
• Headcount: 1-10
• LinkedIn: medexcelcap

Medical Excellence Capital, LLC (MEC) is a private venture capital firm based in New York, founded in 2020. The firm specializes in early-stage investments in the life sciences sector, focusing on innovative medical technologies that tackle significant healthcare challenges. MEC aims to advance precision health by deploying capital to support transformative technologies in areas such as artificial intelligence for drug discovery, cell and gene therapy, and regenerative medicine. The firm has established a proprietary network of physician scientists and experienced investment professionals to identify and nurture promising life sciences ventures. MEC's portfolio includes active companies like Aspen Neuroscience and Immunitas Therapeutics, which are engaged in cutting-edge research and development. Through its investments, MEC plays a crucial role in fostering innovation and addressing unmet medical needs in the biotechnology field.

18. Prevail Therapeutics

• Website: prevailtherapeutics.com
• Ownership type: Corporate
• Headquarters: New York, New York, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: $880.0M, December 2020
• Founded year: 2017
• Headcount: 51-200
• LinkedIn: prevail-therapeutics

Prevail Therapeutics, founded in 2017 and based in New York City, is a biotechnology company dedicated to developing gene therapies aimed at treating neurodegenerative diseases. The company specializes in conditions such as Parkinson's disease, Gaucher disease, and frontotemporal dementia. Prevail's approach leverages recent advancements in human genetics and gene therapy technology, particularly focusing on AAV9-based therapies. Their pipeline includes promising candidates like PR001 and PR006, which are currently in clinical trials. Prevail Therapeutics was acquired by Eli Lilly and Company in 2021, becoming a wholly owned subsidiary. This acquisition has likely enhanced their capabilities and resources in the biotechnology field. The company has received substantial funding, totaling $880 million, which underscores its potential and the importance of its research initiatives in addressing critical health challenges.

19. Aethon Therapeutics

• Website: aethontx.com
• Ownership type: Venture Capital
• Headquarters: New York, New York, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Series A, $30.0M, January 2023
• Founded year: 2022
• Headcount: 11-50
• LinkedIn: aethon-therapeutics

Aethon Therapeutics, based in New York, is a biotechnology firm established in 2022. The company specializes in creating advanced cancer treatment solutions, particularly through the engineering of novel antibodies. Their focus is on developing targeted therapies that specifically address drug-resistant cancer cells. Aethon's proprietary HapImmune™ platform enhances the immune system's ability to recognize and attack tumors, which is crucial in the fight against cancer. The company collaborates with healthcare providers and pharmaceutical companies to deliver innovative therapeutic options. Recently, Aethon secured $30 million in Series A funding, reflecting strong investor interest and support for its mission to transform cancer treatments into effective cures.

20. Itb-med

• Website: itb-med.com
• Ownership type: Private
• Headquarters: New York, New York, United States (USA)
• Employee distribution: Sweden 53%, United States (USA) 47%
• Latest funding: $67.0M, April 2018
• Founded year: 2016
• Headcount: 11-50
• LinkedIn: itbmed-ab

ITB-MED, founded in 2016 and based in New York City, is a biotechnology company dedicated to developing groundbreaking therapies for transplantation and autoimmune diseases. The company is advancing its proprietary monoclonal antibody, TCD601 (siplizumab), through extensive global clinical trials. This therapy aims to provide immunosuppression freedom for transplant patients, potentially enhancing their quality of life and reducing healthcare costs. ITB-MED's clinical pipeline includes various projects in transplantation, such as kidney and liver tolerance, as well as applications in autoimmune conditions like Type-1 diabetes and amyotrophic lateral sclerosis. The company has secured significant funding, amounting to $67 million, which underscores investor confidence in its mission and potential. With a team of experienced professionals and a commitment to innovative research, ITB-MED is positioned to make a meaningful impact in the biotechnology industry.

Biotechnology Companies Insights: Key Companies in New York

Want to Find More Biotechnology Companies Companies?

With Inven you'll also get to know the company's:

• Detailed Ownership: Who owns the company? Is it a public or private company? What is the ownership structure?
• Contact data: Who are the founders and CEO's? What are their emails and phone numbers?
• Financials: How do these companies perform financially? What are their revenues and profit margins?

...and a lot more!